Clinical trial
A Phase I Maximum Tolerated Dose Study of CI-1012 in Late-Stage HIV+ Patients
NCT00002218 · Parke-Davis, Industry · Completed
Key facts
| NCT number | NCT00002218 |
|---|---|
| Title | A Phase I Maximum Tolerated Dose Study of CI-1012 in Late-Stage HIV+ Patients |
| Official title | A Phase I Maximum Tolerated Dose Study of CI-1012 in Late-Stage HIV+ Patients |
| Lead sponsor | Parke-Davis, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | CI-1012 |
| Enrollment | 40 |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: